Study summary · research use only
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this comparative study, the authors examined the anxiolytic effect and tolerability of the peptide selank versus phenazepam in 60 patients with phobic-anxiety and somatoform disorders (ICD-10 F40.2-9, F41.1-9, F45.0-1). The abstract reports pronounced anxiolytic and mild nootropic effects of selank, that the anxiolytic effect lasted for a week after the last dose, and that selank had a positive impact on patients' quality of life. The authors state the data extend therapeutic possibilities in treating anxiety disorders.
Abstract
Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a week after last receiving the peptide. Selank had a positive impact on the quality of life of the patients. Conclusion. The data obtained in the study extend therapeutic possibilities in the treatment of anxiety disorders.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.